Drug intelligence / Profile preview

liquidambar styraciflua pollen

Development stage
Unknown
Lead developer
Greer Laboratories
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal, Percutaneous, Subcutaneous
01

Overview

Liquidambar styraciflua pollen is an allergenic extract derived from the pollen of the sweetgum tree (Liquidambar styraciflua). [18] It is used for both the diagnosis and treatment of individuals with immediate hypersensitivity allergies to this specific pollen. [22] As a non-standardized pollen allergenic extract, it functions as a form of immunotherapy (allergy shots) to desensitize the immune system. [17] The treatment is intended to modulate the body's immune response, encouraging a shift from an allergic IgE-dominant reaction to a tolerance-based state characterized by increased production of IgG antibodies. [17, 22] This reduces the release of histamine and other mediators that cause allergy symptoms. [17, 22] It is administered via percutaneous, intradermal, or subcutaneous injection for skin testing and hyposensitization. The product, first approved in the U.S. in 1965, is marketed by companies such as ALK-Abello and Stallergenes Greer. [19]

Brand names
Sweetgum PollenSweetgum
Other names
Sweet Gum PollenAmerican sweetgum pollen
02

Targets

High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complexIgE (Immunoglobulin E)

Beyond the preview

Go deeper on liquidambar styraciflua pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on liquidambar styraciflua pollen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call